Ascelia Pharma
11.16 SEK +5.28%HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read moreLatest research
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sunstone life Science Ventures Fund II K/S | 13.7 % | 14.1 % |
Avanza Pension | 8.2 % | 8.4 % |
Premium
This content is for our Premium customers only.
Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits